EMERGENT BIOSOLUTIONS INC. Increase (Decrease) in Income Taxes Receivable
EMERGENT BIOSOLUTIONS INC. (EBS) reported Increase (Decrease) in Income Taxes Receivable of $11.70 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2020-02-25
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes receivable for the quarter ending 2018-12-31 was -$5.03M.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes receivable for the quarter ending 2018-09-30 was $6.89M, a 24.95% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes receivable for the quarter ending 2018-06-30 was $3.13M.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes receivable for the quarter ending 2018-03-31 was $113.00K.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes receivable for fiscal 2019 was $11.70M, a 129.41% increase from fiscal 2018.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes receivable for fiscal 2018 was $5.10M.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes receivable for fiscal 2017 was -$20.10M, a 691.18% decline from fiscal 2016.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes receivable for fiscal 2016 was $3.40M, a 38.09% decline from fiscal 2015.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 6 month as first filed | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 9 month as first filed | Increase (Decrease) in Income Taxes Receivable 12 month | Increase (Decrease) in Income Taxes Receivable 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | $11.70M 10-K · filed 2020-02-25 | ||||||
| 2018-12-31 | -$5.03M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $1.86M derived: sum of 2 quarters · filed 2020-02-25 | $4.99M derived: sum of 3 quarters · filed 2020-02-25 | $5.10M 10-K · filed 2020-02-25 | |||
| 2018-09-30 | $6.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $10.02M derived: sum of 2 quarters · filed 2018-11-02 | $10.13M 10-Q · filed 2018-11-02 | -$15.48M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-06-30 | $3.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $3.24M 10-Q · filed 2018-08-03 | -$22.38M derived: sum of 3 quarters · filed 2020-02-25 | -$16.86M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-03-31 | $113.00K 10-Q · filed 2018-05-04 | -$25.50M derived: sum of 2 quarters · filed 2020-02-25 | -$19.99M derived: sum of 3 quarters · filed 2020-02-25 | -$19.99M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2017-12-31 | -$25.61M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$20.10M derived: sum of 2 quarters · filed 2020-02-25 | -$20.10M derived: sum of 3 quarters · filed 2020-02-25 | -$20.10M 10-K · filed 2020-02-25 | -$20.07M 10-K · filed 2018-02-23 | ||
| 2017-09-30 | $5.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $5.51M derived: sum of 2 quarters · filed 2018-11-02 | $5.51M 10-Q · filed 2018-11-02 | -$1.16M derived: sum of 4 quarters · filed 2019-02-22 | |||
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $0.00 10-Q · filed 2018-08-03 | -$6.67M derived: sum of 3 quarters · filed 2019-02-22 | -$6.66M derived: sum of 4 quarters · filed 2019-02-22 | |||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-04 | -$6.67M derived: sum of 2 quarters · filed 2019-02-22 | -$6.66M derived: sum of 3 quarters · filed 2019-02-22 | -$976.00K derived: sum of 4 quarters · filed 2019-02-22 | |||
| 2016-12-31 | -$6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$6.66M derived: sum of 2 quarters · filed 2019-02-22 | -$976.00K derived: sum of 3 quarters · filed 2019-02-22 | $3.40M 10-K · filed 2019-02-22 | $4.56M 10-K · filed 2017-02-28 | ||
| 2016-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $5.70M derived: sum of 2 quarters · filed 2017-11-03 | $10.07M 10-Q · filed 2017-11-03 | -$14.66M 10-Q · filed 2016-11-09 | $38.27M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2016-06-30 | $5.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $10.06M 10-Q · filed 2017-08-04 | $14.56M 10-Q · filed 2016-08-05 | $38.26M derived: sum of 3 quarters · filed 2018-02-23 | -$1.18M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2016-03-31 | $4.38M 10-Q · filed 2016-05-06 | $32.58M derived: sum of 2 quarters · filed 2018-02-23 | -$6.87M derived: sum of 3 quarters · filed 2018-02-23 | -$2.29M derived: sum of 4 quarters · filed 2018-02-23 | |||
| 2015-12-31 | $28.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | -$11.25M derived: sum of 2 quarters · filed 2018-02-23 | -$6.67M derived: sum of 3 quarters · filed 2018-02-23 | $5.49M 10-K · filed 2018-02-23 | $3.55M 10-K · filed 2016-02-29 | ||
| 2015-09-30 | -$39.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$34.87M derived: sum of 2 quarters · filed 2016-11-09 | -$22.71M 10-Q · filed 2016-11-09 | $22.71M 10-Q · filed 2015-11-06 | -$22.44M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-06-30 | $4.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $16.74M 10-Q · filed 2016-08-05 | $17.00M derived: sum of 3 quarters · filed 2017-02-28 | $16.27M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | $12.16M 10-Q · filed 2016-05-06 | $12.42M derived: sum of 2 quarters · filed 2017-02-28 | $11.69M derived: sum of 3 quarters · filed 2017-02-28 | $13.12M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | $264.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$473.00K derived: sum of 2 quarters · filed 2017-02-28 | $958.00K derived: sum of 3 quarters · filed 2017-02-28 | $4.71M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | -$737.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $694.00K derived: sum of 2 quarters · filed 2015-11-06 | $4.45M 10-Q · filed 2015-11-06 | $4.70M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $5.18M 10-Q · filed 2015-08-06 | $5.44M derived: sum of 3 quarters · filed 2016-02-29 | $4.36M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $3.75M 10-Q · filed 2015-05-08 | $4.00M derived: sum of 2 quarters · filed 2016-02-29 | $2.93M derived: sum of 3 quarters · filed 2016-02-29 | $3.01M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $252.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$820.00K derived: sum of 2 quarters · filed 2016-02-29 | -$739.00K derived: sum of 3 quarters · filed 2016-02-29 | $7.18M 10-K · filed 2016-02-29 | |||
| 2013-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$991.00K derived: sum of 2 quarters · filed 2014-11-10 | $6.93M 10-Q · filed 2014-11-10 | -$2.73M derived: sum of 4 quarters · filed 2015-03-09 | |||
| 2013-06-30 | $81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $8.00M 10-Q · filed 2014-08-08 | -$1.65M derived: sum of 3 quarters · filed 2015-03-09 | -$2.22M derived: sum of 4 quarters · filed 2015-03-09 | |||
| 2013-03-31 | $7.92M 10-Q · filed 2014-05-12 | -$1.73M derived: sum of 2 quarters · filed 2015-03-09 | -$2.30M derived: sum of 3 quarters · filed 2015-03-09 | -$11.29M derived: sum of 4 quarters · filed 2015-03-09 | |||
| 2012-12-31 | -$9.65M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | -$10.22M derived: sum of 2 quarters · filed 2015-03-09 | -$19.21M derived: sum of 3 quarters · filed 2015-03-09 | -$8.05M 10-K · filed 2015-03-09 | |||
| 2012-09-30 | -$566.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | -$9.56M derived: sum of 2 quarters · filed 2013-11-08 | $1.60M 10-Q · filed 2013-11-08 | -$15.59M derived: sum of 4 quarters · filed 2014-03-10 | |||
| 2012-06-30 | -$8.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $2.16M 10-Q · filed 2013-08-06 | -$15.02M derived: sum of 3 quarters · filed 2014-03-10 | -$7.67M derived: sum of 4 quarters · filed 2014-03-10 | |||
| 2012-03-31 | $11.15M 10-Q · filed 2013-05-03 | -$6.03M derived: sum of 2 quarters · filed 2014-03-10 | $1.32M derived: sum of 3 quarters · filed 2014-03-10 | -$5.51M derived: sum of 4 quarters · filed 2014-03-10 | |||
| 2011-12-31 | -$17.18M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | -$9.83M derived: sum of 2 quarters · filed 2014-03-10 | -$16.66M derived: sum of 3 quarters · filed 2014-03-10 | -$1.42M 10-K · filed 2014-03-10 | |||
| 2011-09-30 | $7.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $522.00K derived: sum of 2 quarters · filed 2012-11-01 | $15.76M 10-Q · filed 2012-11-01 | -$15.76M 10-Q · filed 2011-11-04 | $30.85M derived: sum of 4 quarters · filed 2013-03-08 | ||
| 2011-06-30 | -$6.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $8.41M 10-Q · filed 2012-08-03 | -$8.41M 10-Q · filed 2011-08-05 | $23.49M derived: sum of 3 quarters · filed 2013-03-08 | $19.08M derived: sum of 4 quarters · filed 2013-03-08 | ||
| 2011-03-31 | $15.24M 10-Q · filed 2012-05-04 | $30.32M derived: sum of 2 quarters · filed 2013-03-08 | $25.91M derived: sum of 3 quarters · filed 2013-03-08 | ||||
| 2010-12-31 | $15.09M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $10.67M derived: sum of 2 quarters · filed 2013-03-08 | $4.45M 10-K · filed 2013-03-08 | ||||
| 2010-09-30 | -$4.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | -$10.63M 10-Q · filed 2011-11-04 | |||||
| 2010-06-30 | -$6.21M 10-Q · filed 2011-08-05 | ||||||
| 2009-12-31 | $1.67M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |